ATE474048T1 - Her2/neu fusionsproteine - Google Patents
Her2/neu fusionsproteineInfo
- Publication number
- ATE474048T1 ATE474048T1 AT00905800T AT00905800T ATE474048T1 AT E474048 T1 ATE474048 T1 AT E474048T1 AT 00905800 T AT00905800 T AT 00905800T AT 00905800 T AT00905800 T AT 00905800T AT E474048 T1 ATE474048 T1 AT E474048T1
- Authority
- AT
- Austria
- Prior art keywords
- fusion proteins
- neu
- neu fusion
- her2
- nucleic acid
- Prior art date
Links
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 title abstract 8
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 title abstract 8
- 102000037865 fusion proteins Human genes 0.000 title abstract 5
- 108020001507 fusion proteins Proteins 0.000 title abstract 5
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 108700020796 Oncogene Proteins 0.000 abstract 1
- 108010059722 Viral Fusion Proteins Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000036210 malignancy Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 239000013603 viral vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11797699P | 1999-01-29 | 1999-01-29 | |
| PCT/US2000/002164 WO2000044899A1 (en) | 1999-01-29 | 2000-01-28 | Her-2/neu fusion proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE474048T1 true ATE474048T1 (de) | 2010-07-15 |
Family
ID=22375831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00905800T ATE474048T1 (de) | 1999-01-29 | 2000-01-28 | Her2/neu fusionsproteine |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP1147190B1 (de) |
| JP (1) | JP5164300B2 (de) |
| KR (1) | KR100766653B1 (de) |
| CN (1) | CN1201004C (de) |
| AT (1) | ATE474048T1 (de) |
| AU (1) | AU780109B2 (de) |
| BR (1) | BR0007840A (de) |
| CA (1) | CA2361009C (de) |
| CZ (1) | CZ20012587A3 (de) |
| DE (1) | DE60044665D1 (de) |
| ES (1) | ES2348708T3 (de) |
| HU (1) | HUP0105303A2 (de) |
| IL (1) | IL144371A0 (de) |
| MX (1) | MXPA01007721A (de) |
| NO (1) | NO20013701L (de) |
| NZ (1) | NZ513062A (de) |
| TR (1) | TR200102191T2 (de) |
| WO (1) | WO2000044899A1 (de) |
| ZA (1) | ZA200106179B (de) |
Families Citing this family (100)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7198920B1 (en) | 1999-01-29 | 2007-04-03 | Corika Corporation | HER-2/neu fusion proteins |
| US7378096B2 (en) | 1999-09-30 | 2008-05-27 | Health Research, Inc. | Stress protein compositions and methods for prevention and treatment of cancer and infectious disease |
| WO2001023421A2 (en) | 1999-09-30 | 2001-04-05 | Corixa Corporation | Stress protein compositions and methods for prevention and treatment of cancer and infectious disease |
| AU2744201A (en) * | 1999-12-29 | 2001-07-09 | Corixa Corporation | Murine neu sequences and methods of use therefor |
| ATE507295T1 (de) * | 2000-03-30 | 2011-05-15 | Dendreon Corp | Zusammensetzungen und verfahren für eine auf dendritischen zellen basierende immuntherapie |
| US7229623B1 (en) | 2000-08-03 | 2007-06-12 | Corixa Corporation | Her-2/neu fusion proteins |
| WO2002014503A2 (en) * | 2000-08-14 | 2002-02-21 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of her-2/neu-associated malignancies |
| DK2266603T3 (da) | 2000-10-18 | 2012-11-05 | Glaxosmithkline Biolog Sa | Tumorvacciner |
| BR0114786A (pt) * | 2000-10-18 | 2003-08-12 | Glaxosmithkline Biolog Sa | Composição imunogênica, método de tratamento de um paciente que sofre de, ou que é suscetìvel a, um câncer, e, uso de uma combinação de uma saponina, um oligotìdeo imunoestimulador e um antìgeno de câncer, e, método para a manufatura de uma composição |
| GB0109297D0 (en) | 2001-04-12 | 2001-05-30 | Glaxosmithkline Biolog Sa | Vaccine |
| EP1417236A4 (de) | 2001-07-10 | 2010-03-17 | Corixa Corp | Zusammensetzungen und verfahren zur abgabe von proteinen und adjuvantien in einer mikrokügelchen-kapsel |
| US20050276812A1 (en) | 2004-06-01 | 2005-12-15 | Genentech, Inc. | Antibody-drug conjugates and methods |
| EP1590437A4 (de) * | 2003-01-24 | 2008-06-18 | Agensys Inc | Für behandlung und nachweis von krebs geeignete nukleinsäuren und entsprechende proteine mit der bezeichnung 254p1d6b |
| US8105615B2 (en) | 2003-06-06 | 2012-01-31 | Agennix Incorporated | Lactoferrin as an adjuvant in cancer vaccines |
| MXPA05013389A (es) * | 2003-06-25 | 2006-03-17 | Pharmexa As | Purificacion de variantes her-2. |
| KR20060033870A (ko) | 2003-06-25 | 2006-04-20 | 파멕사 에이/에스 | Ｈｅｒ-2 변이체의 정제 |
| NZ544543A (en) * | 2003-07-21 | 2009-03-31 | Angeletti P Ist Richerche Bio | Synthetic gene encoding human epidermal growth factor 2/neu antigen and uses thereof |
| GB0321615D0 (en) | 2003-09-15 | 2003-10-15 | Glaxo Group Ltd | Improvements in vaccination |
| CN107213469A (zh) | 2003-11-06 | 2017-09-29 | 西雅图基因公司 | 能够与配体偶联的单甲基缬氨酸化合物 |
| US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
| KR101270829B1 (ko) | 2004-09-23 | 2013-06-07 | 제넨테크, 인크. | 시스테인 유전자조작 항체 및 접합체 |
| ITMI20041965A1 (it) * | 2004-10-15 | 2005-01-15 | Augusto Amici | "dna codificante forme tronche e chimeriche della proteina p185neu e suoi usi terapeutici" |
| GB0427131D0 (en) * | 2004-12-10 | 2005-01-12 | Glaxosmithkline Biolog Sa | Novel combination |
| TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| EP2390360A1 (de) | 2006-06-02 | 2011-11-30 | GlaxoSmithKline Biologicals S.A. | Verfahren zur Indentifizierung des Ansprechens bzw. Nichtansprechens eines Patienten auf eine Immuntherapie basierend auf die Differentielle Expression vom Gen IDO1 |
| CA2687632C (en) | 2007-05-24 | 2013-01-15 | Glaxosmithkline Biologicals S.A. | Lyophilised antigen composition |
| CA2809819A1 (en) | 2009-09-09 | 2011-03-17 | Centrose, Llc | Extracellular targeted drug conjugates |
| GB0917457D0 (en) | 2009-10-06 | 2009-11-18 | Glaxosmithkline Biolog Sa | Method |
| WO2011130598A1 (en) | 2010-04-15 | 2011-10-20 | Spirogen Limited | Pyrrolobenzodiazepines and conjugates thereof |
| MX336540B (es) | 2010-06-08 | 2016-01-22 | Genentech Inc | Conjugados y anticuerpos manipulados geneticamente con cisteina. |
| ES2544608T3 (es) | 2010-11-17 | 2015-09-02 | Genentech, Inc. | Conjugados de anticuerpo y de alaninil-maitansinol |
| MX2013013054A (es) | 2011-05-12 | 2014-02-20 | Genentech Inc | Metodo de monitoreo de lc-ms/ms de reaccion multiple para detectar anticuerpos terapeuticos en muestras de animales utilizando peptidos de firma de estructura. |
| WO2013055987A1 (en) | 2011-10-14 | 2013-04-18 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
| WO2013130093A1 (en) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Biomarkers for treatment with anti-tubulin chemotherapeutic compounds |
| HRP20181646T2 (hr) | 2012-10-12 | 2019-08-09 | Adc Therapeutics Sa | Konjugati pirolobenzodiazepin - anti-psma protutijela |
| ES2680153T3 (es) | 2012-10-12 | 2018-09-04 | Adc Therapeutics Sa | Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas |
| KR101645905B1 (ko) | 2012-10-12 | 2016-08-04 | 스피로즌 살 | 피롤로벤조디아제핀 및 그의 컨주게이트 |
| WO2014057120A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| PL2906251T3 (pl) | 2012-10-12 | 2018-02-28 | Adc Therapeutics Sa | Koniugaty pirolobenzodiazepina-przeciwciało anty-CD22 |
| WO2014057117A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| MX364328B (es) | 2012-10-12 | 2019-04-23 | Medimmune Ltd | Conjugados del anticuerpo pirrolobenzodiazepina. |
| CN105246894A (zh) | 2012-12-21 | 2016-01-13 | 斯皮罗根有限公司 | 用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物 |
| AU2013366493B2 (en) | 2012-12-21 | 2017-08-24 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| WO2014140862A2 (en) | 2013-03-13 | 2014-09-18 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| JP6445519B2 (ja) | 2013-03-13 | 2018-12-26 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | ピロロベンゾジアゼピン及びそのコンジュゲート |
| EP2968585B1 (de) | 2013-03-13 | 2018-07-18 | Medimmune Limited | Pyrrolobenzodiazepine und konjugate davon |
| US10442836B2 (en) | 2013-08-12 | 2019-10-15 | Genentech, Inc. | 1-(chloromethyl)-2,3-dihydro-1H-benzo[E]indole dimer antibody-drug conjugate compounds, and methods of use and treatment |
| US10010624B2 (en) | 2013-10-11 | 2018-07-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| US9950078B2 (en) | 2013-10-11 | 2018-04-24 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| EP3054986B1 (de) | 2013-10-11 | 2019-03-20 | Medimmune Limited | Pyrrolobenzodiazepin-antikörper-konjugate |
| JP6425327B2 (ja) * | 2013-12-12 | 2018-11-21 | 国立大学法人東京農工大学 | タンパク質−磁性粒子複合体及びその製造方法 |
| BR112016013258A2 (pt) | 2013-12-16 | 2018-01-16 | Genentech Inc | composto conjugado anticorpo-droga, composição farmacêutica, método para tratar câncer e kit |
| CA2928952A1 (en) | 2013-12-16 | 2015-06-25 | Genentech, Inc. | Peptidomimetic compounds and antibody-drug conjugates thereof |
| JP6895254B2 (ja) | 2013-12-16 | 2021-06-30 | ジェネンテック， インコーポレイテッド | ペプチド模倣化合物及びその抗体−薬物コンジュゲート |
| WO2016037644A1 (en) | 2014-09-10 | 2016-03-17 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| US10077318B2 (en) | 2014-09-12 | 2018-09-18 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
| GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| US10149913B2 (en) | 2014-09-12 | 2018-12-11 | Genentech, Inc. | Anthracycline disulfide intermediates, antibody-drug conjugates and methods |
| JP2017533887A (ja) | 2014-09-17 | 2017-11-16 | ジェネンテック， インコーポレイテッド | ピロロベンゾジアゼピン類及びその抗体ジスルフィドコンジュゲート |
| US10780096B2 (en) | 2014-11-25 | 2020-09-22 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| CA2969689A1 (en) | 2014-12-03 | 2016-06-09 | Genentech, Inc. | Quaternary amine compounds and antibody-drug conjugates thereof |
| GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| NZ741261A (en) | 2015-10-02 | 2019-11-29 | Genentech Inc | Pyrrolobenzodiazepine antibody drug conjugates and methods of use |
| MA43354A (fr) | 2015-10-16 | 2018-08-22 | Genentech Inc | Conjugués médicamenteux à pont disulfure encombré |
| EP3365025B1 (de) | 2015-10-20 | 2020-07-15 | Genentech, Inc. | Calicheamicin-antikörper-arzneimittelkonjugate und verfahren zur verwendung |
| GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
| GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| EP3433621A1 (de) | 2016-03-25 | 2019-01-30 | H. Hoffnabb-La Roche Ag | Multiplex-gesamtantikörper- und antikörper-konjugierter arzneimittelquantifizierungstest |
| GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| CN118436801A (zh) | 2016-05-20 | 2024-08-06 | 豪夫迈·罗氏有限公司 | Protac抗体缀合物及其使用方法 |
| US20170370906A1 (en) | 2016-05-27 | 2017-12-28 | Genentech, Inc. | Bioanalytical analysis of site-specific antibody drug conjugates |
| EP3464280B1 (de) | 2016-06-06 | 2021-10-06 | F. Hoffmann-La Roche AG | Silvestrol-antikörper-arzneimittelkonjugate und verfahren zur verwendung |
| WO2018031662A1 (en) | 2016-08-11 | 2018-02-15 | Genentech, Inc. | Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof |
| JP7050770B2 (ja) | 2016-10-05 | 2022-04-08 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 抗体薬物コンジュゲートの調製方法 |
| GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
| UA125198C2 (uk) | 2017-02-08 | 2022-01-26 | Ейдісі Терапьютікс Са | Кон'югати піролобензодіазепін-антитіло |
| SI3612537T1 (sl) | 2017-04-18 | 2022-10-28 | Medimmune Limited | Konjugati pirolobenzodiazepina |
| WO2018193102A1 (en) | 2017-04-20 | 2018-10-25 | Adc Therapeutics Sa | Combination therapy with an anti-axl antibody-drug conjugate |
| JP7145891B2 (ja) | 2017-06-14 | 2022-10-03 | アーデーセー セラピューティクス ソシエテ アノニム | 抗ｃｄ１９ ａｄｃを投与するための投与レジメ |
| BR112020003003A2 (pt) | 2017-08-18 | 2020-08-11 | Medimmune Limited | conjugados de pirrolobenzodiazepina |
| AU2018337815A1 (en) | 2017-09-20 | 2020-03-12 | Ph Pharma Co., Ltd. | Thailanstatin analogs |
| GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
| GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| GB201814281D0 (en) | 2018-09-03 | 2018-10-17 | Femtogenix Ltd | Cytotoxic agents |
| WO2020086858A1 (en) | 2018-10-24 | 2020-04-30 | Genentech, Inc. | Conjugated chemical inducers of degradation and methods of use |
| EP3894427A1 (de) | 2018-12-10 | 2021-10-20 | Genentech, Inc. | Photovernetzende peptide zur stellenspezifischen konjugation an fc-haltige proteine |
| GB201901197D0 (en) | 2019-01-29 | 2019-03-20 | Femtogenix Ltd | G-A Crosslinking cytotoxic agents |
| MX2021010477A (es) | 2019-03-15 | 2021-10-01 | Medimmune Ltd | Dimeros de azetidobenzodiazepina y conjugados que los comprenden para uso en el tratamiento de cancer. |
| WO2022013189A1 (en) * | 2020-07-14 | 2022-01-20 | F. Hoffmann-La Roche Ag | Assays for fixed dose combinations |
| GB2597532A (en) | 2020-07-28 | 2022-02-02 | Femtogenix Ltd | Cytotoxic compounds |
| WO2022078524A2 (en) | 2021-11-03 | 2022-04-21 | Hangzhou Dac Biotech Co., Ltd. | Specific conjugation of an antibody |
| JP2026502860A (ja) | 2022-12-23 | 2026-01-27 | ジェネンテック， インコーポレイテッド | セレブロン分解剤コンジュゲートおよびその使用 |
| KR102584276B1 (ko) * | 2023-03-30 | 2023-10-10 | 주식회사 애스톤사이언스 | Her2 백신, 및 면역관문 억제제의 조합 요법 |
| CN121263210A (zh) | 2023-04-17 | 2026-01-02 | 沛科生物公司 | 抗体和抗体-药物偶联物以及使用方法和合成工艺及中间体 |
| WO2026006688A2 (en) | 2024-06-28 | 2026-01-02 | Firefly Bio, Inc. | Degrader antibody conjugates and uses thereof |
| WO2026006689A2 (en) | 2024-06-28 | 2026-01-02 | Firefly Bio, Inc. | Bcl-xl degrader antibody conjugates and uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2055441C (en) * | 1989-05-19 | 2003-01-07 | Robert M. Hudziak | Her2 extracellular domain |
| US5801005A (en) * | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
| JPH0914357A (ja) * | 1995-06-27 | 1997-01-14 | Honda Motor Co Ltd | 伝動ベルト用ブロック |
-
2000
- 2000-01-28 DE DE60044665T patent/DE60044665D1/de not_active Expired - Lifetime
- 2000-01-28 EP EP00905800A patent/EP1147190B1/de not_active Expired - Lifetime
- 2000-01-28 TR TR2001/02191T patent/TR200102191T2/xx unknown
- 2000-01-28 CA CA2361009A patent/CA2361009C/en not_active Expired - Fee Related
- 2000-01-28 MX MXPA01007721A patent/MXPA01007721A/es not_active Application Discontinuation
- 2000-01-28 IL IL14437100A patent/IL144371A0/xx unknown
- 2000-01-28 AU AU27426/00A patent/AU780109B2/en not_active Ceased
- 2000-01-28 JP JP2000596141A patent/JP5164300B2/ja not_active Expired - Fee Related
- 2000-01-28 NZ NZ513062A patent/NZ513062A/en unknown
- 2000-01-28 KR KR1020017009563A patent/KR100766653B1/ko not_active Expired - Fee Related
- 2000-01-28 AT AT00905800T patent/ATE474048T1/de not_active IP Right Cessation
- 2000-01-28 CN CNB008057524A patent/CN1201004C/zh not_active Expired - Fee Related
- 2000-01-28 BR BR0007840-9A patent/BR0007840A/pt not_active IP Right Cessation
- 2000-01-28 ES ES00905800T patent/ES2348708T3/es not_active Expired - Lifetime
- 2000-01-28 WO PCT/US2000/002164 patent/WO2000044899A1/en not_active Ceased
- 2000-01-28 HU HU0105303A patent/HUP0105303A2/hu unknown
- 2000-01-28 CZ CZ20012587A patent/CZ20012587A3/cs unknown
-
2001
- 2001-07-26 ZA ZA200106179A patent/ZA200106179B/en unknown
- 2001-07-27 NO NO20013701A patent/NO20013701L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL144371A0 (en) | 2002-05-23 |
| AU780109B2 (en) | 2005-03-03 |
| KR20010101865A (ko) | 2001-11-15 |
| HUP0105303A2 (en) | 2002-05-29 |
| CA2361009C (en) | 2012-10-23 |
| KR100766653B1 (ko) | 2007-10-15 |
| CA2361009A1 (en) | 2000-08-03 |
| AU2742600A (en) | 2000-08-18 |
| WO2000044899A1 (en) | 2000-08-03 |
| DE60044665D1 (de) | 2010-08-26 |
| JP2002535004A (ja) | 2002-10-22 |
| TR200102191T2 (tr) | 2001-12-21 |
| NO20013701L (no) | 2001-09-28 |
| EP1147190B1 (de) | 2010-07-14 |
| NZ513062A (en) | 2003-10-31 |
| CN1345374A (zh) | 2002-04-17 |
| ZA200106179B (en) | 2002-12-24 |
| NO20013701D0 (no) | 2001-07-27 |
| CN1201004C (zh) | 2005-05-11 |
| BR0007840A (pt) | 2002-01-22 |
| CZ20012587A3 (cs) | 2002-05-15 |
| HK1044798A1 (en) | 2002-11-01 |
| ES2348708T3 (es) | 2010-12-13 |
| JP5164300B2 (ja) | 2013-03-21 |
| MXPA01007721A (es) | 2003-07-14 |
| EP1147190A1 (de) | 2001-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE474048T1 (de) | Her2/neu fusionsproteine | |
| WO2002012341A3 (en) | Her-2/neu fusion proteins | |
| HUP0302532A2 (hu) | Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások | |
| BR0113921A (pt) | ácidos nucléicos e polipeptìdeos receptores | |
| UA93855C2 (ru) | Вакцина, способствует росту, базирующейся ha нейтрализующем эпитопе | |
| DE69634912D1 (de) | Intrazellulare domäne des her-2/neu proteins, für die prevention oder behandlung von bösartigen tumoren | |
| FI932678A0 (fi) | Pao alfavirus baserande DNA expressionssystem | |
| CY1114265T1 (el) | Πρωτεϊνη συντηξης αλβουμινης | |
| HUP0002095A2 (hu) | Vegyületek prosztatarák immunterápiás kezelésére és alkalmazásuk | |
| BR9608615A (pt) | Vacinas de vírus sincicial respiratório de ácido nucléico | |
| BRPI0511118A (pt) | polipeptìdeos de haemophilus influenzae não transcritos | |
| WO2002080851A3 (en) | Chimeric vaccines | |
| MY209387A (en) | Multi-specific binding proteins for cancer treatment | |
| DE69929310D1 (de) | Tumorassoziierte antigenderivate der mage-familie, nukleinsäuresequenzen die dafür kodieren, zur herstellung von fusionsproteinen und zusammensetzungen zur impfung | |
| CY1107351T1 (el) | Καινοφανης μεταλλαγμενη μορφη απιμινασης αργινινης | |
| BRPI0507579A (pt) | molécula de ácido nucleico, vetor, célula hospedeira, processo para expressar uma proteìna de fusão cea em uma célula hospedeira recombinante, proteìna de fusão cea purificada, método de prevenção ou tratamento de cáncer, plasmìdeo de vacina, e, método de tratamento de um mamìfero sofrendo de ou predisposto a um cáncer associados com cea | |
| PT97103A (pt) | Moleculas de acido nucleico isoladas e vacinas contra gp75 que as contem | |
| EP1536006A4 (de) | Krebsantigene und deren nutzung | |
| DK1082423T3 (da) | Cyclin E2-gener og -proteiner | |
| DK1290160T3 (da) | Humane Pellino-polypeptider | |
| WO1999065517A3 (en) | Therapeutic compositions that produce an immune response by altering the antigen | |
| AU6987696A (en) | The use of the wap of mmtv regulatory sequences for targeted expression of linked heterologous genes in human mammary cells, including human mammary carcinoma cells | |
| ATE381351T1 (de) | Anwendung des herpes simplex virus glykoproteins- d zur unterdrückung von immunantworten | |
| BRPI0409321A (pt) | antìgeno hìbrido, competição e método para induzir uma resposta imune para um agente infeccioso ou antìgeno de tumor, método para tratar uma doença infecciosa ou cáncer, e, peptìdeo | |
| BR0110791A (pt) | Composição, métodos para induzir uma resposta imune em um indivìduo contra um imunogene, para modular o sistema imune de um indivìduo e para imunizar um indivìduo contra um patógeno, vacina recombinante, e patógeno atenuado vivo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |